Q2 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX)

Immix Biopharma, Inc. (NASDAQ:IMMX) – HC Wainwright issued their Q2 2024 earnings per share (EPS) estimates for shares of Immix Biopharma in a research note issued on Monday, July 1st. HC Wainwright analyst R. Burns expects that the company will post earnings per share of ($0.21) for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.21) EPS, Q4 2024 earnings at ($0.19) EPS, FY2024 earnings at ($0.83) EPS, Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.67) EPS.

Immix Biopharma Price Performance

Shares of NASDAQ IMMX opened at $2.45 on Wednesday. The stock has a market capitalization of $64.70 million, a price-to-earnings ratio of -2.63 and a beta of 0.17. The business has a 50-day moving average of $2.17 and a 200-day moving average of $3.35. Immix Biopharma has a fifty-two week low of $1.55 and a fifty-two week high of $7.75.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01.

Hedge Funds Weigh In On Immix Biopharma

Several hedge funds have recently modified their holdings of the stock. Private Advisor Group LLC bought a new position in Immix Biopharma during the fourth quarter worth about $690,000. Tritonpoint Wealth LLC acquired a new position in Immix Biopharma during the first quarter worth approximately $75,000. Jump Financial LLC acquired a new position in Immix Biopharma during the fourth quarter worth approximately $128,000. Tocqueville Asset Management L.P. increased its position in Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after buying an additional 17,800 shares during the last quarter. Finally, Imprint Wealth LLC increased its position in Immix Biopharma by 49.4% during the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after buying an additional 11,400 shares during the last quarter. Institutional investors own 11.26% of the company’s stock.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.